Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research

Ahmet Emre Eskazan, Mario Tiribelli,